Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (greater than or equal to 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

Trial Profile

A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (greater than or equal to 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bendamustine (Primary) ; Ibrutinib (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2018 Results assessing efficacy of Ibrutinib was superior in comparison with treatment with bendamustine plus rituximab in untreated patients with Chronic lymphocytic leukaemia, published in the New England Journal of Medicine.
    • 31 Aug 2018 Biomarkers information updated
    • 03 May 2018 Planned primary completion date changed from 16 May 2018 to 28 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top